Active — Not RecruitingNot Applicable

Advancing Precision Lung Cancer Surveillance and Outcomes in Diverse Populations

United States1,826 participantsStarted 2012-01

Plain-language summary

This observational study evaluates the effectiveness of computed tomography (CT) imaging surveillance after curative-intent treatment for stage I-IIIA non-small cell lung cancer (NSCLC) in a diverse U.S. population. The main questions are: How do CT surveillance use and adherence vary by race, ethnicity, and socioeconomic status? Does semi-annual CT surveillance improve outcomes compared with annual surveillance? Adults ages 20-90 with stage I-IIIA NSCLC treated between 2012 and 2026 will be identified using OneFlorida+ electronic health records, tumor registry data, claims, and clinical notes. Patients will be followed for up to five years after curative-intent therapy to evaluate surveillance patterns, recurrence, second primary lung cancers, complications, and survival.

Who can participate

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Adults diagnosed with primary, pathologically confirmed stage I-IIIA non- small cell lung cancer (NSCLC). * Received curative-intent therapy, including: Surgical resection, or Stereotactic body radiation therapy (SBRT), with or without adjuvant therapy. * Completed curative-intent therapy and survived at least 5 months after therapy initiation. * Received care within the University of Florida (Gainesville or Jacksonville) health system, and are included in the OneFlorida+ clinical data network. * Have available: Structured EHR data (including tumor registry linkage, imaging, procedures, and vital statistics), and Unstructured clinical documents (clinic notes, radiology reports, pathology reports) enable NLP extraction. \- Have ≥1 follow-up encounter in the EHR after treatment completion to allow surveillance assessment. Exclusion Criteria: * Histology other than NSCLC, including: Small-cell lung cancer Carcinoid tumors Rare non-NSCLC primary tumors * Metastatic disease (stage IV) at diagnosis. * No curative-intent therapy received (e.g., palliative treatment only). * Patients with incomplete treatment records prevent the determination of the treatment completion date. * Patients with no surveillance-relevant follow-up data, including: No post-treatment clinical notes No radiology/pathology records No linked tumor registry or vital status data * Patients with recurrence or who die within the first 5 months after starting curative-intent therapy…

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Guideline Adherence to Chest CT Surveillance

Timeframe: Up to 5 years after treatment completion

Annual Rates of Guideline-Concordant Surveillance CT Imaging during post-treatment Years 1-5.

Timeframe: Year-specific rates are assessed annually for up to 5 years post-treatment.

Time to First Recurrence

Timeframe: Up to 5 years post-treatment.

Time to Second Primary Lung Cancer (SPLC)

Timeframe: Up to 5 years or end of follow up

All-cause mortality

Timeframe: Up to 5 years post-treatment (or longest available follow-up).

Lung Cancer-Specific Mortality

Timeframe: Up to 5 years following treatment completion.

Mode of Recurrence Detection

Timeframe: Assessed at the time of recurrence, up to 5 years following treatment completion.

Trial details

NCT IDNCT07581379

SponsorUniversity of Florida

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2026-12

View on ClinicalTrials.gov More Lung Neoplasms trials